In partnership with Sanofi, this combination regimen is currently being evaluated in two phase 2 studies, one in advanced ovarian cancer and one in neoadjuvant breast cancer.Methodology & Results
- A total of 28 patients with certain platinum resistant gynecological cancers or HER2 non-overexpressing breast cancer received a combination of MM-121 and weekly paclitaxel until disease progression or intolerable toxicity was reported. Response was assessed every eight weeks.
- The observed safety profile of MM-121 in combination with weekly paclitaxel suggest a similar toxicity profile to that of weekly paclitaxel alone.
- Across all dosing cohorts, the overall clinical benefit rate was 70 percent. Forty-eight percent achieved a partial response (PR) and of those, 39 percent achieved a confirmed PR with a median duration of 2.7 months (range 1.7 – 15.1 months). Twenty-two percent experienced stable disease (SD) >4 months with a median duration of 5.3 months. Nine percent of patients had progressive disease (PD) at first assessment and 26 percent remain on study with a median on-study time of 13.5 months in 23 evaluable patients.